IO Biotech(IOBT)
COPENHAGEN, Denmark
BiotechnologyFocus: Immuno-Oncology
IO Biotech is a life sciences company focused on Immuno-Oncology.
Oncology
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
PD-L1/IDO Peptide Vaccine
High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaClinical Trials (1)
NCT05843448IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
Phase 1IO102
NSCLCClinical Trials (1)
NCT03562871IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC
Phase 1/2PD-L1 peptide
Smoldering Multiple MyelomaClinical Trials (1)
NCT03850522PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma
Phase 2Pembrolizumab
Head and Neck Squamous Cell CarcinomaClinical Trials (1)
NCT05977907Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Phase 2IO102-IO103 in combination with pembrolizumab
Lung Cancer Non Small CellClinical Trials (1)
NCT05077709IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
Phase 2IO102/IO103
MelanomaClinical Trials (1)
NCT05912244A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
Phase 2PD-L1, PD-L2 peptides with Montanide ISA51
Chronic Lymphocytic LeukemiaClinical Trials (1)
NCT03939234Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.
Phase 2IO102-IO103
MelanomaClinical Trials (1)
NCT05280314Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Phase 2IO102-IO103
Metastatic MelanomaClinical Trials (1)
NCT05155254IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2012
Portfolio: 9 clinical trials
Top TAs: Oncology
SEC Filings: 2 available